WuXi XDC Cayman Inc.
Research WuXi XDC Cayman Inc. (2268.HK) on Bullrun: market cap HKD 94.28B, P/E 58.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2268.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyHKD
- Market capHKD 94.28B
- P/E58.2
- Financial periodFY2025
- RevenueCNY 5.94B
- Revenue growth46.7%
- Net incomeCNY 1.48B
- Free cash flowCNY 523.52M
- Gross margin36.0%
Valuation Snapshot
latest market cap is HKD 94.28B; P/E is 58.2.
Peer valuation comparison
Latest P/E is 58.16x versus a Healthcare sector median of 21.69x (168.1% above).
Latest P/E is 58.16x versus a China median of 16.26x (257.6% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 5.94B | CNY 1.48B | CNY 523.52M | 36.0% | 1.12 | CNY 1.51B | CNY 879.14M | CNY 10.73B |
| FY2024 | CNY 4.05B | CNY 1.07B | -CNY 787.95M | 30.6% | 0.83 | CNY 1.93B | CNY 496.43M | CNY 6.64B |
| FY2023 | CNY 2.12B | CNY 283.54M | -CNY 206.52M | 26.3% | 0.26 | CNY 4.05B | CNY 2.84M | CNY 5.45B |
| FY2022 | CNY 990.42M | CNY 155.73M | CNY 50.43M | 26.4% | 0.13 | CNY 334.97M | CNY 77.18M | CNY 1.48B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 94.28B | 58.2 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About WuXi XDC Cayman Inc.
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is WuXi XDC Cayman Inc.'s market cap?
WuXi XDC Cayman Inc.'s market capitalization is HKD 94.28B.
What is WuXi XDC Cayman Inc.'s P/E ratio?
WuXi XDC Cayman Inc.'s price-to-earnings (P/E) ratio is 58.2.
What does WuXi XDC Cayman Inc. do?
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, manufacturing, and marketing of anti-tumor drugs.